nodes	percent_of_prediction	percent_of_DWPC	metapath
Clomipramine—GSTP1—Chlorambucil—ovarian cancer	0.39	0.637	CbGbCtD
Clomipramine—ABCB1—ovarian cancer	0.167	1	CbGaD
Clomipramine—GSTP1—Carboplatin—ovarian cancer	0.126	0.206	CbGbCtD
Clomipramine—ABCB1—Topotecan—ovarian cancer	0.0177	0.0289	CbGbCtD
Clomipramine—ABCB1—Vinorelbine—ovarian cancer	0.0125	0.0204	CbGbCtD
Clomipramine—CYP2D6—Vinorelbine—ovarian cancer	0.0118	0.0192	CbGbCtD
Clomipramine—CYP3A4—Topotecan—ovarian cancer	0.0106	0.0173	CbGbCtD
Clomipramine—ABCB1—Paclitaxel—ovarian cancer	0.00876	0.0143	CbGbCtD
Clomipramine—CYP3A4—Vinorelbine—ovarian cancer	0.00747	0.0122	CbGbCtD
Clomipramine—ABCB1—Docetaxel—ovarian cancer	0.00634	0.0103	CbGbCtD
Clomipramine—CYP3A4—Paclitaxel—ovarian cancer	0.00525	0.00857	CbGbCtD
Clomipramine—ABCB1—Doxorubicin—ovarian cancer	0.00472	0.00771	CbGbCtD
Clomipramine—CYP2D6—Doxorubicin—ovarian cancer	0.00445	0.00727	CbGbCtD
Clomipramine—CYP3A4—Docetaxel—ovarian cancer	0.0038	0.0062	CbGbCtD
Clomipramine—GSTP1—oviduct—ovarian cancer	0.00359	0.0961	CbGeAlD
Clomipramine—CYP3A4—Doxorubicin—ovarian cancer	0.00283	0.00462	CbGbCtD
Clomipramine—HTR2A—vein—ovarian cancer	0.00257	0.0688	CbGeAlD
Clomipramine—GSTP1—myometrium—ovarian cancer	0.00115	0.0308	CbGeAlD
Clomipramine—GSTP1—embryo—ovarian cancer	0.00111	0.0296	CbGeAlD
Clomipramine—HTR2B—myometrium—ovarian cancer	0.000948	0.0254	CbGeAlD
Clomipramine—GSTP1—epithelium—ovarian cancer	0.000903	0.0241	CbGeAlD
Clomipramine—GSTP1—uterine cervix—ovarian cancer	0.000895	0.0239	CbGeAlD
Clomipramine—GSTP1—decidua—ovarian cancer	0.000853	0.0228	CbGeAlD
Clomipramine—GSTP1—endometrium—ovarian cancer	0.00081	0.0216	CbGeAlD
Clomipramine—GSTP1—gonad—ovarian cancer	0.000751	0.0201	CbGeAlD
Clomipramine—GSTP1—uterus—ovarian cancer	0.000746	0.0199	CbGeAlD
Clomipramine—HTR2B—uterine cervix—ovarian cancer	0.000738	0.0197	CbGeAlD
Clomipramine—HTR2B—decidua—ovarian cancer	0.000703	0.0188	CbGeAlD
Clomipramine—GSTP1—female reproductive system—ovarian cancer	0.000671	0.0179	CbGeAlD
Clomipramine—HTR2B—endometrium—ovarian cancer	0.000668	0.0178	CbGeAlD
Clomipramine—GSTP1—bone marrow—ovarian cancer	0.000633	0.0169	CbGeAlD
Clomipramine—SLC6A2—decidua—ovarian cancer	0.000625	0.0167	CbGeAlD
Clomipramine—HTR2B—uterus—ovarian cancer	0.000615	0.0164	CbGeAlD
Clomipramine—GSTP1—female gonad—ovarian cancer	0.00061	0.0163	CbGeAlD
Clomipramine—GSTP1—vagina—ovarian cancer	0.000606	0.0162	CbGeAlD
Clomipramine—ADRA2A—myometrium—ovarian cancer	0.000596	0.0159	CbGeAlD
Clomipramine—HTR2C—female reproductive system—ovarian cancer	0.000589	0.0157	CbGeAlD
Clomipramine—SLC6A4—female reproductive system—ovarian cancer	0.000558	0.0149	CbGeAlD
Clomipramine—HTR2B—female reproductive system—ovarian cancer	0.000553	0.0148	CbGeAlD
Clomipramine—SLC6A2—gonad—ovarian cancer	0.00055	0.0147	CbGeAlD
Clomipramine—HRH2—lymph node—ovarian cancer	0.000545	0.0146	CbGeAlD
Clomipramine—GSTP1—testis—ovarian cancer	0.000541	0.0145	CbGeAlD
Clomipramine—HTR2B—vagina—ovarian cancer	0.0005	0.0134	CbGeAlD
Clomipramine—SLC6A2—female reproductive system—ovarian cancer	0.000491	0.0131	CbGeAlD
Clomipramine—HTR2A—embryo—ovarian cancer	0.000487	0.013	CbGeAlD
Clomipramine—ADRA2A—uterine cervix—ovarian cancer	0.000464	0.0124	CbGeAlD
Clomipramine—ALB—testis—ovarian cancer	0.000463	0.0124	CbGeAlD
Clomipramine—ADRA2A—decidua—ovarian cancer	0.000442	0.0118	CbGeAlD
Clomipramine—ADRA2A—endometrium—ovarian cancer	0.000419	0.0112	CbGeAlD
Clomipramine—CYP2C19—vagina—ovarian cancer	0.000418	0.0112	CbGeAlD
Clomipramine—HTR2A—epithelium—ovarian cancer	0.000398	0.0106	CbGeAlD
Clomipramine—SLC6A2—testis—ovarian cancer	0.000397	0.0106	CbGeAlD
Clomipramine—GSTP1—lymph node—ovarian cancer	0.000392	0.0105	CbGeAlD
Clomipramine—ADRA2A—gonad—ovarian cancer	0.000389	0.0104	CbGeAlD
Clomipramine—ADRA2A—uterus—ovarian cancer	0.000386	0.0103	CbGeAlD
Clomipramine—ADRA2A—female reproductive system—ovarian cancer	0.000347	0.00929	CbGeAlD
Clomipramine—ALB—lymph node—ovarian cancer	0.000336	0.00898	CbGeAlD
Clomipramine—ABCB1—myometrium—ovarian cancer	0.000332	0.00887	CbGeAlD
Clomipramine—HTR2A—gonad—ovarian cancer	0.000331	0.00884	CbGeAlD
Clomipramine—HTR2B—lymph node—ovarian cancer	0.000323	0.00865	CbGeAlD
Clomipramine—ABCB1—embryo—ovarian cancer	0.000319	0.00853	CbGeAlD
Clomipramine—ADRA2A—female gonad—ovarian cancer	0.000316	0.00845	CbGeAlD
Clomipramine—ADRA2A—vagina—ovarian cancer	0.000314	0.0084	CbGeAlD
Clomipramine—HTR2A—female reproductive system—ovarian cancer	0.000295	0.0079	CbGeAlD
Clomipramine—SLC6A2—lymph node—ovarian cancer	0.000287	0.00768	CbGeAlD
Clomipramine—ADRA2A—testis—ovarian cancer	0.00028	0.00749	CbGeAlD
Clomipramine—CYP3A4—female reproductive system—ovarian cancer	0.000273	0.00731	CbGeAlD
Clomipramine—CYP2D6—female reproductive system—ovarian cancer	0.000269	0.00719	CbGeAlD
Clomipramine—HTR2A—vagina—ovarian cancer	0.000267	0.00714	CbGeAlD
Clomipramine—ABCB1—epithelium—ovarian cancer	0.00026	0.00696	CbGeAlD
Clomipramine—ABCB1—uterine cervix—ovarian cancer	0.000258	0.00691	CbGeAlD
Clomipramine—ABCB1—decidua—ovarian cancer	0.000246	0.00658	CbGeAlD
Clomipramine—CYP2D6—female gonad—ovarian cancer	0.000245	0.00654	CbGeAlD
Clomipramine—HTR2A—testis—ovarian cancer	0.000238	0.00637	CbGeAlD
Clomipramine—ABCB1—endometrium—ovarian cancer	0.000234	0.00625	CbGeAlD
Clomipramine—CYP2D6—testis—ovarian cancer	0.000217	0.0058	CbGeAlD
Clomipramine—ABCB1—gonad—ovarian cancer	0.000217	0.00579	CbGeAlD
Clomipramine—ABCB1—uterus—ovarian cancer	0.000215	0.00576	CbGeAlD
Clomipramine—ADRA2A—lymph node—ovarian cancer	0.000203	0.00543	CbGeAlD
Clomipramine—ABCB1—female reproductive system—ovarian cancer	0.000194	0.00517	CbGeAlD
Clomipramine—ABCB1—bone marrow—ovarian cancer	0.000183	0.00488	CbGeAlD
Clomipramine—ABCB1—female gonad—ovarian cancer	0.000176	0.00471	CbGeAlD
Clomipramine—ABCB1—vagina—ovarian cancer	0.000175	0.00468	CbGeAlD
Clomipramine—ABCB1—testis—ovarian cancer	0.000156	0.00418	CbGeAlD
Clomipramine—ABCB1—lymph node—ovarian cancer	0.000113	0.00303	CbGeAlD
Clomipramine—Conjunctivitis—Epirubicin—ovarian cancer	7.55e-05	0.000462	CcSEcCtD
Clomipramine—Urinary tract infection—Epirubicin—ovarian cancer	7.55e-05	0.000462	CcSEcCtD
Clomipramine—Dysuria—Doxorubicin—ovarian cancer	7.54e-05	0.000461	CcSEcCtD
Clomipramine—Decreased appetite—Paclitaxel—ovarian cancer	7.53e-05	0.000461	CcSEcCtD
Clomipramine—Dry mouth—Docetaxel—ovarian cancer	7.49e-05	0.000458	CcSEcCtD
Clomipramine—Gastrointestinal disorder—Paclitaxel—ovarian cancer	7.48e-05	0.000457	CcSEcCtD
Clomipramine—Fatigue—Paclitaxel—ovarian cancer	7.47e-05	0.000457	CcSEcCtD
Clomipramine—Sweating—Epirubicin—ovarian cancer	7.45e-05	0.000455	CcSEcCtD
Clomipramine—Pollakiuria—Doxorubicin—ovarian cancer	7.45e-05	0.000455	CcSEcCtD
Clomipramine—Constipation—Paclitaxel—ovarian cancer	7.41e-05	0.000453	CcSEcCtD
Clomipramine—Pain—Paclitaxel—ovarian cancer	7.41e-05	0.000453	CcSEcCtD
Clomipramine—Haematuria—Epirubicin—ovarian cancer	7.41e-05	0.000453	CcSEcCtD
Clomipramine—Confusional state—Docetaxel—ovarian cancer	7.41e-05	0.000453	CcSEcCtD
Clomipramine—Photosensitivity reaction—Doxorubicin—ovarian cancer	7.36e-05	0.00045	CcSEcCtD
Clomipramine—Hepatobiliary disease—Epirubicin—ovarian cancer	7.35e-05	0.000449	CcSEcCtD
Clomipramine—Oedema—Docetaxel—ovarian cancer	7.35e-05	0.000449	CcSEcCtD
Clomipramine—Anaphylactic shock—Docetaxel—ovarian cancer	7.35e-05	0.000449	CcSEcCtD
Clomipramine—Weight increased—Doxorubicin—ovarian cancer	7.34e-05	0.000448	CcSEcCtD
Clomipramine—Epistaxis—Epirubicin—ovarian cancer	7.33e-05	0.000448	CcSEcCtD
Clomipramine—Weight decreased—Doxorubicin—ovarian cancer	7.29e-05	0.000446	CcSEcCtD
Clomipramine—Sinusitis—Epirubicin—ovarian cancer	7.29e-05	0.000446	CcSEcCtD
Clomipramine—Hyperglycaemia—Doxorubicin—ovarian cancer	7.27e-05	0.000445	CcSEcCtD
Clomipramine—Agranulocytosis—Epirubicin—ovarian cancer	7.25e-05	0.000443	CcSEcCtD
Clomipramine—Pneumonia—Doxorubicin—ovarian cancer	7.23e-05	0.000442	CcSEcCtD
Clomipramine—Shock—Docetaxel—ovarian cancer	7.23e-05	0.000442	CcSEcCtD
Clomipramine—Nervous system disorder—Docetaxel—ovarian cancer	7.2e-05	0.00044	CcSEcCtD
Clomipramine—Thrombocytopenia—Docetaxel—ovarian cancer	7.19e-05	0.00044	CcSEcCtD
Clomipramine—Drowsiness—Doxorubicin—ovarian cancer	7.19e-05	0.000439	CcSEcCtD
Clomipramine—Tachycardia—Docetaxel—ovarian cancer	7.17e-05	0.000438	CcSEcCtD
Clomipramine—Feeling abnormal—Paclitaxel—ovarian cancer	7.14e-05	0.000437	CcSEcCtD
Clomipramine—Skin disorder—Docetaxel—ovarian cancer	7.14e-05	0.000436	CcSEcCtD
Clomipramine—Bradycardia—Epirubicin—ovarian cancer	7.1e-05	0.000434	CcSEcCtD
Clomipramine—Gastrointestinal pain—Paclitaxel—ovarian cancer	7.09e-05	0.000433	CcSEcCtD
Clomipramine—Neuropathy peripheral—Doxorubicin—ovarian cancer	7.05e-05	0.000431	CcSEcCtD
Clomipramine—Jaundice—Doxorubicin—ovarian cancer	7.01e-05	0.000428	CcSEcCtD
Clomipramine—Anorexia—Docetaxel—ovarian cancer	7e-05	0.000428	CcSEcCtD
Clomipramine—Rhinitis—Epirubicin—ovarian cancer	6.99e-05	0.000427	CcSEcCtD
Clomipramine—Urinary tract infection—Doxorubicin—ovarian cancer	6.99e-05	0.000427	CcSEcCtD
Clomipramine—Conjunctivitis—Doxorubicin—ovarian cancer	6.99e-05	0.000427	CcSEcCtD
Clomipramine—Hepatitis—Epirubicin—ovarian cancer	6.97e-05	0.000426	CcSEcCtD
Clomipramine—Hypoaesthesia—Epirubicin—ovarian cancer	6.94e-05	0.000424	CcSEcCtD
Clomipramine—Pharyngitis—Epirubicin—ovarian cancer	6.92e-05	0.000423	CcSEcCtD
Clomipramine—Sweating—Doxorubicin—ovarian cancer	6.89e-05	0.000421	CcSEcCtD
Clomipramine—Urinary tract disorder—Epirubicin—ovarian cancer	6.89e-05	0.000421	CcSEcCtD
Clomipramine—Urticaria—Paclitaxel—ovarian cancer	6.89e-05	0.000421	CcSEcCtD
Clomipramine—Hypotension—Docetaxel—ovarian cancer	6.86e-05	0.00042	CcSEcCtD
Clomipramine—Haematuria—Doxorubicin—ovarian cancer	6.85e-05	0.000419	CcSEcCtD
Clomipramine—Connective tissue disorder—Epirubicin—ovarian cancer	6.85e-05	0.000419	CcSEcCtD
Clomipramine—Abdominal pain—Paclitaxel—ovarian cancer	6.85e-05	0.000419	CcSEcCtD
Clomipramine—Body temperature increased—Paclitaxel—ovarian cancer	6.85e-05	0.000419	CcSEcCtD
Clomipramine—Urethral disorder—Epirubicin—ovarian cancer	6.84e-05	0.000418	CcSEcCtD
Clomipramine—Hepatobiliary disease—Doxorubicin—ovarian cancer	6.8e-05	0.000416	CcSEcCtD
Clomipramine—Epistaxis—Doxorubicin—ovarian cancer	6.78e-05	0.000414	CcSEcCtD
Clomipramine—Sinusitis—Doxorubicin—ovarian cancer	6.74e-05	0.000412	CcSEcCtD
Clomipramine—Visual impairment—Epirubicin—ovarian cancer	6.72e-05	0.000411	CcSEcCtD
Clomipramine—Agranulocytosis—Doxorubicin—ovarian cancer	6.71e-05	0.00041	CcSEcCtD
Clomipramine—Musculoskeletal discomfort—Docetaxel—ovarian cancer	6.69e-05	0.000409	CcSEcCtD
Clomipramine—Insomnia—Docetaxel—ovarian cancer	6.64e-05	0.000406	CcSEcCtD
Clomipramine—Paraesthesia—Docetaxel—ovarian cancer	6.6e-05	0.000403	CcSEcCtD
Clomipramine—Bradycardia—Doxorubicin—ovarian cancer	6.57e-05	0.000402	CcSEcCtD
Clomipramine—Dyspnoea—Docetaxel—ovarian cancer	6.55e-05	0.0004	CcSEcCtD
Clomipramine—Somnolence—Docetaxel—ovarian cancer	6.53e-05	0.000399	CcSEcCtD
Clomipramine—Eye disorder—Epirubicin—ovarian cancer	6.52e-05	0.000398	CcSEcCtD
Clomipramine—Tinnitus—Epirubicin—ovarian cancer	6.5e-05	0.000397	CcSEcCtD
Clomipramine—Cardiac disorder—Epirubicin—ovarian cancer	6.47e-05	0.000396	CcSEcCtD
Clomipramine—Flushing—Epirubicin—ovarian cancer	6.47e-05	0.000396	CcSEcCtD
Clomipramine—Rhinitis—Doxorubicin—ovarian cancer	6.47e-05	0.000395	CcSEcCtD
Clomipramine—Dyspepsia—Docetaxel—ovarian cancer	6.47e-05	0.000395	CcSEcCtD
Clomipramine—Hepatitis—Doxorubicin—ovarian cancer	6.45e-05	0.000394	CcSEcCtD
Clomipramine—Hypoaesthesia—Doxorubicin—ovarian cancer	6.42e-05	0.000392	CcSEcCtD
Clomipramine—Pharyngitis—Doxorubicin—ovarian cancer	6.41e-05	0.000391	CcSEcCtD
Clomipramine—Decreased appetite—Docetaxel—ovarian cancer	6.39e-05	0.00039	CcSEcCtD
Clomipramine—Hypersensitivity—Paclitaxel—ovarian cancer	6.39e-05	0.00039	CcSEcCtD
Clomipramine—Urinary tract disorder—Doxorubicin—ovarian cancer	6.37e-05	0.00039	CcSEcCtD
Clomipramine—Gastrointestinal disorder—Docetaxel—ovarian cancer	6.34e-05	0.000388	CcSEcCtD
Clomipramine—Connective tissue disorder—Doxorubicin—ovarian cancer	6.34e-05	0.000388	CcSEcCtD
Clomipramine—Fatigue—Docetaxel—ovarian cancer	6.33e-05	0.000387	CcSEcCtD
Clomipramine—Angiopathy—Epirubicin—ovarian cancer	6.33e-05	0.000387	CcSEcCtD
Clomipramine—Urethral disorder—Doxorubicin—ovarian cancer	6.33e-05	0.000387	CcSEcCtD
Clomipramine—Immune system disorder—Epirubicin—ovarian cancer	6.3e-05	0.000385	CcSEcCtD
Clomipramine—Mediastinal disorder—Epirubicin—ovarian cancer	6.29e-05	0.000384	CcSEcCtD
Clomipramine—Constipation—Docetaxel—ovarian cancer	6.28e-05	0.000384	CcSEcCtD
Clomipramine—Pain—Docetaxel—ovarian cancer	6.28e-05	0.000384	CcSEcCtD
Clomipramine—Chills—Epirubicin—ovarian cancer	6.26e-05	0.000383	CcSEcCtD
Clomipramine—Arrhythmia—Epirubicin—ovarian cancer	6.23e-05	0.000381	CcSEcCtD
Clomipramine—Visual impairment—Doxorubicin—ovarian cancer	6.22e-05	0.00038	CcSEcCtD
Clomipramine—Asthenia—Paclitaxel—ovarian cancer	6.22e-05	0.00038	CcSEcCtD
Clomipramine—Alopecia—Epirubicin—ovarian cancer	6.16e-05	0.000377	CcSEcCtD
Clomipramine—Pruritus—Paclitaxel—ovarian cancer	6.13e-05	0.000375	CcSEcCtD
Clomipramine—Mental disorder—Epirubicin—ovarian cancer	6.11e-05	0.000373	CcSEcCtD
Clomipramine—Malnutrition—Epirubicin—ovarian cancer	6.07e-05	0.000371	CcSEcCtD
Clomipramine—Feeling abnormal—Docetaxel—ovarian cancer	6.05e-05	0.00037	CcSEcCtD
Clomipramine—Eye disorder—Doxorubicin—ovarian cancer	6.03e-05	0.000369	CcSEcCtD
Clomipramine—Tinnitus—Doxorubicin—ovarian cancer	6.02e-05	0.000368	CcSEcCtD
Clomipramine—Gastrointestinal pain—Docetaxel—ovarian cancer	6.01e-05	0.000367	CcSEcCtD
Clomipramine—Flushing—Doxorubicin—ovarian cancer	5.99e-05	0.000366	CcSEcCtD
Clomipramine—Cardiac disorder—Doxorubicin—ovarian cancer	5.99e-05	0.000366	CcSEcCtD
Clomipramine—Flatulence—Epirubicin—ovarian cancer	5.98e-05	0.000366	CcSEcCtD
Clomipramine—Tension—Epirubicin—ovarian cancer	5.96e-05	0.000364	CcSEcCtD
Clomipramine—Dysgeusia—Epirubicin—ovarian cancer	5.95e-05	0.000363	CcSEcCtD
Clomipramine—Diarrhoea—Paclitaxel—ovarian cancer	5.93e-05	0.000362	CcSEcCtD
Clomipramine—Nervousness—Epirubicin—ovarian cancer	5.9e-05	0.00036	CcSEcCtD
Clomipramine—Back pain—Epirubicin—ovarian cancer	5.87e-05	0.000359	CcSEcCtD
Clomipramine—Angiopathy—Doxorubicin—ovarian cancer	5.86e-05	0.000358	CcSEcCtD
Clomipramine—Muscle spasms—Epirubicin—ovarian cancer	5.84e-05	0.000357	CcSEcCtD
Clomipramine—Immune system disorder—Doxorubicin—ovarian cancer	5.83e-05	0.000356	CcSEcCtD
Clomipramine—Mediastinal disorder—Doxorubicin—ovarian cancer	5.82e-05	0.000355	CcSEcCtD
Clomipramine—Abdominal pain—Docetaxel—ovarian cancer	5.81e-05	0.000355	CcSEcCtD
Clomipramine—Body temperature increased—Docetaxel—ovarian cancer	5.81e-05	0.000355	CcSEcCtD
Clomipramine—Chills—Doxorubicin—ovarian cancer	5.79e-05	0.000354	CcSEcCtD
Clomipramine—Arrhythmia—Doxorubicin—ovarian cancer	5.77e-05	0.000352	CcSEcCtD
Clomipramine—Dizziness—Paclitaxel—ovarian cancer	5.73e-05	0.00035	CcSEcCtD
Clomipramine—Vision blurred—Epirubicin—ovarian cancer	5.72e-05	0.00035	CcSEcCtD
Clomipramine—Alopecia—Doxorubicin—ovarian cancer	5.7e-05	0.000349	CcSEcCtD
Clomipramine—Mental disorder—Doxorubicin—ovarian cancer	5.65e-05	0.000346	CcSEcCtD
Clomipramine—Ill-defined disorder—Epirubicin—ovarian cancer	5.63e-05	0.000344	CcSEcCtD
Clomipramine—Malnutrition—Doxorubicin—ovarian cancer	5.62e-05	0.000343	CcSEcCtD
Clomipramine—Anaemia—Epirubicin—ovarian cancer	5.61e-05	0.000343	CcSEcCtD
Clomipramine—Agitation—Epirubicin—ovarian cancer	5.58e-05	0.000341	CcSEcCtD
Clomipramine—Flatulence—Doxorubicin—ovarian cancer	5.54e-05	0.000338	CcSEcCtD
Clomipramine—Tension—Doxorubicin—ovarian cancer	5.51e-05	0.000337	CcSEcCtD
Clomipramine—Vomiting—Paclitaxel—ovarian cancer	5.51e-05	0.000337	CcSEcCtD
Clomipramine—Dysgeusia—Doxorubicin—ovarian cancer	5.5e-05	0.000336	CcSEcCtD
Clomipramine—Malaise—Epirubicin—ovarian cancer	5.48e-05	0.000335	CcSEcCtD
Clomipramine—Rash—Paclitaxel—ovarian cancer	5.46e-05	0.000334	CcSEcCtD
Clomipramine—Dermatitis—Paclitaxel—ovarian cancer	5.46e-05	0.000334	CcSEcCtD
Clomipramine—Nervousness—Doxorubicin—ovarian cancer	5.46e-05	0.000333	CcSEcCtD
Clomipramine—Vertigo—Epirubicin—ovarian cancer	5.45e-05	0.000333	CcSEcCtD
Clomipramine—Syncope—Epirubicin—ovarian cancer	5.44e-05	0.000333	CcSEcCtD
Clomipramine—Leukopenia—Epirubicin—ovarian cancer	5.43e-05	0.000332	CcSEcCtD
Clomipramine—Back pain—Doxorubicin—ovarian cancer	5.43e-05	0.000332	CcSEcCtD
Clomipramine—Headache—Paclitaxel—ovarian cancer	5.43e-05	0.000332	CcSEcCtD
Clomipramine—Hypersensitivity—Docetaxel—ovarian cancer	5.41e-05	0.000331	CcSEcCtD
Clomipramine—Muscle spasms—Doxorubicin—ovarian cancer	5.4e-05	0.00033	CcSEcCtD
Clomipramine—Palpitations—Epirubicin—ovarian cancer	5.37e-05	0.000328	CcSEcCtD
Clomipramine—Loss of consciousness—Epirubicin—ovarian cancer	5.34e-05	0.000326	CcSEcCtD
Clomipramine—Cough—Epirubicin—ovarian cancer	5.3e-05	0.000324	CcSEcCtD
Clomipramine—Vision blurred—Doxorubicin—ovarian cancer	5.29e-05	0.000324	CcSEcCtD
Clomipramine—Asthenia—Docetaxel—ovarian cancer	5.27e-05	0.000322	CcSEcCtD
Clomipramine—Convulsion—Epirubicin—ovarian cancer	5.26e-05	0.000322	CcSEcCtD
Clomipramine—Hypertension—Epirubicin—ovarian cancer	5.24e-05	0.00032	CcSEcCtD
Clomipramine—Ill-defined disorder—Doxorubicin—ovarian cancer	5.21e-05	0.000319	CcSEcCtD
Clomipramine—Pruritus—Docetaxel—ovarian cancer	5.2e-05	0.000318	CcSEcCtD
Clomipramine—Anaemia—Doxorubicin—ovarian cancer	5.19e-05	0.000317	CcSEcCtD
Clomipramine—Chest pain—Epirubicin—ovarian cancer	5.17e-05	0.000316	CcSEcCtD
Clomipramine—Arthralgia—Epirubicin—ovarian cancer	5.17e-05	0.000316	CcSEcCtD
Clomipramine—Myalgia—Epirubicin—ovarian cancer	5.17e-05	0.000316	CcSEcCtD
Clomipramine—Agitation—Doxorubicin—ovarian cancer	5.16e-05	0.000316	CcSEcCtD
Clomipramine—Anxiety—Epirubicin—ovarian cancer	5.15e-05	0.000315	CcSEcCtD
Clomipramine—Nausea—Paclitaxel—ovarian cancer	5.15e-05	0.000315	CcSEcCtD
Clomipramine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	5.13e-05	0.000314	CcSEcCtD
Clomipramine—Discomfort—Epirubicin—ovarian cancer	5.11e-05	0.000312	CcSEcCtD
Clomipramine—Triflupromazine—ABCB1—ovarian cancer	5.08e-05	0.121	CrCbGaD
Clomipramine—Malaise—Doxorubicin—ovarian cancer	5.07e-05	0.00031	CcSEcCtD
Clomipramine—Dry mouth—Epirubicin—ovarian cancer	5.06e-05	0.000309	CcSEcCtD
Clomipramine—Vertigo—Doxorubicin—ovarian cancer	5.05e-05	0.000308	CcSEcCtD
Clomipramine—Syncope—Doxorubicin—ovarian cancer	5.04e-05	0.000308	CcSEcCtD
Clomipramine—Leukopenia—Doxorubicin—ovarian cancer	5.03e-05	0.000307	CcSEcCtD
Clomipramine—Diarrhoea—Docetaxel—ovarian cancer	5.03e-05	0.000307	CcSEcCtD
Clomipramine—Confusional state—Epirubicin—ovarian cancer	5e-05	0.000305	CcSEcCtD
Clomipramine—Palpitations—Doxorubicin—ovarian cancer	4.96e-05	0.000303	CcSEcCtD
Clomipramine—Anaphylactic shock—Epirubicin—ovarian cancer	4.96e-05	0.000303	CcSEcCtD
Clomipramine—Oedema—Epirubicin—ovarian cancer	4.96e-05	0.000303	CcSEcCtD
Clomipramine—Loss of consciousness—Doxorubicin—ovarian cancer	4.94e-05	0.000302	CcSEcCtD
Clomipramine—Cough—Doxorubicin—ovarian cancer	4.9e-05	0.0003	CcSEcCtD
Clomipramine—Shock—Epirubicin—ovarian cancer	4.88e-05	0.000298	CcSEcCtD
Clomipramine—Convulsion—Doxorubicin—ovarian cancer	4.87e-05	0.000298	CcSEcCtD
Clomipramine—Nervous system disorder—Epirubicin—ovarian cancer	4.86e-05	0.000297	CcSEcCtD
Clomipramine—Dizziness—Docetaxel—ovarian cancer	4.86e-05	0.000297	CcSEcCtD
Clomipramine—Thrombocytopenia—Epirubicin—ovarian cancer	4.85e-05	0.000297	CcSEcCtD
Clomipramine—Hypertension—Doxorubicin—ovarian cancer	4.85e-05	0.000296	CcSEcCtD
Clomipramine—Tachycardia—Epirubicin—ovarian cancer	4.84e-05	0.000296	CcSEcCtD
Clomipramine—Skin disorder—Epirubicin—ovarian cancer	4.81e-05	0.000294	CcSEcCtD
Clomipramine—Hyperhidrosis—Epirubicin—ovarian cancer	4.79e-05	0.000293	CcSEcCtD
Clomipramine—Myalgia—Doxorubicin—ovarian cancer	4.78e-05	0.000292	CcSEcCtD
Clomipramine—Arthralgia—Doxorubicin—ovarian cancer	4.78e-05	0.000292	CcSEcCtD
Clomipramine—Chest pain—Doxorubicin—ovarian cancer	4.78e-05	0.000292	CcSEcCtD
Clomipramine—Anxiety—Doxorubicin—ovarian cancer	4.77e-05	0.000291	CcSEcCtD
Clomipramine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	4.75e-05	0.00029	CcSEcCtD
Clomipramine—Discomfort—Doxorubicin—ovarian cancer	4.73e-05	0.000289	CcSEcCtD
Clomipramine—Anorexia—Epirubicin—ovarian cancer	4.72e-05	0.000289	CcSEcCtD
Clomipramine—Dry mouth—Doxorubicin—ovarian cancer	4.68e-05	0.000286	CcSEcCtD
Clomipramine—Vomiting—Docetaxel—ovarian cancer	4.67e-05	0.000285	CcSEcCtD
Clomipramine—Rash—Docetaxel—ovarian cancer	4.63e-05	0.000283	CcSEcCtD
Clomipramine—Hypotension—Epirubicin—ovarian cancer	4.63e-05	0.000283	CcSEcCtD
Clomipramine—Dermatitis—Docetaxel—ovarian cancer	4.63e-05	0.000283	CcSEcCtD
Clomipramine—Confusional state—Doxorubicin—ovarian cancer	4.62e-05	0.000283	CcSEcCtD
Clomipramine—Headache—Docetaxel—ovarian cancer	4.6e-05	0.000281	CcSEcCtD
Clomipramine—Anaphylactic shock—Doxorubicin—ovarian cancer	4.58e-05	0.00028	CcSEcCtD
Clomipramine—Oedema—Doxorubicin—ovarian cancer	4.58e-05	0.00028	CcSEcCtD
Clomipramine—Clobazam—ABCB1—ovarian cancer	4.52e-05	0.108	CrCbGaD
Clomipramine—Musculoskeletal discomfort—Epirubicin—ovarian cancer	4.51e-05	0.000276	CcSEcCtD
Clomipramine—Shock—Doxorubicin—ovarian cancer	4.51e-05	0.000276	CcSEcCtD
Clomipramine—Nervous system disorder—Doxorubicin—ovarian cancer	4.5e-05	0.000275	CcSEcCtD
Clomipramine—Thrombocytopenia—Doxorubicin—ovarian cancer	4.49e-05	0.000274	CcSEcCtD
Clomipramine—Insomnia—Epirubicin—ovarian cancer	4.48e-05	0.000274	CcSEcCtD
Clomipramine—Tachycardia—Doxorubicin—ovarian cancer	4.47e-05	0.000274	CcSEcCtD
Clomipramine—Skin disorder—Doxorubicin—ovarian cancer	4.45e-05	0.000272	CcSEcCtD
Clomipramine—Paraesthesia—Epirubicin—ovarian cancer	4.45e-05	0.000272	CcSEcCtD
Clomipramine—Hyperhidrosis—Doxorubicin—ovarian cancer	4.43e-05	0.000271	CcSEcCtD
Clomipramine—Dyspnoea—Epirubicin—ovarian cancer	4.42e-05	0.00027	CcSEcCtD
Clomipramine—Somnolence—Epirubicin—ovarian cancer	4.41e-05	0.000269	CcSEcCtD
Clomipramine—Anorexia—Doxorubicin—ovarian cancer	4.37e-05	0.000267	CcSEcCtD
Clomipramine—Nausea—Docetaxel—ovarian cancer	4.36e-05	0.000267	CcSEcCtD
Clomipramine—Dyspepsia—Epirubicin—ovarian cancer	4.36e-05	0.000267	CcSEcCtD
Clomipramine—Decreased appetite—Epirubicin—ovarian cancer	4.31e-05	0.000263	CcSEcCtD
Clomipramine—Hypotension—Doxorubicin—ovarian cancer	4.28e-05	0.000262	CcSEcCtD
Clomipramine—Gastrointestinal disorder—Epirubicin—ovarian cancer	4.28e-05	0.000261	CcSEcCtD
Clomipramine—Fatigue—Epirubicin—ovarian cancer	4.27e-05	0.000261	CcSEcCtD
Clomipramine—Pain—Epirubicin—ovarian cancer	4.24e-05	0.000259	CcSEcCtD
Clomipramine—Constipation—Epirubicin—ovarian cancer	4.24e-05	0.000259	CcSEcCtD
Clomipramine—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	4.18e-05	0.000255	CcSEcCtD
Clomipramine—Insomnia—Doxorubicin—ovarian cancer	4.15e-05	0.000253	CcSEcCtD
Clomipramine—Paraesthesia—Doxorubicin—ovarian cancer	4.12e-05	0.000252	CcSEcCtD
Clomipramine—Dyspnoea—Doxorubicin—ovarian cancer	4.09e-05	0.00025	CcSEcCtD
Clomipramine—Feeling abnormal—Epirubicin—ovarian cancer	4.08e-05	0.00025	CcSEcCtD
Clomipramine—Somnolence—Doxorubicin—ovarian cancer	4.08e-05	0.000249	CcSEcCtD
Clomipramine—Gastrointestinal pain—Epirubicin—ovarian cancer	4.05e-05	0.000248	CcSEcCtD
Clomipramine—Dyspepsia—Doxorubicin—ovarian cancer	4.04e-05	0.000247	CcSEcCtD
Clomipramine—Decreased appetite—Doxorubicin—ovarian cancer	3.99e-05	0.000244	CcSEcCtD
Clomipramine—Gastrointestinal disorder—Doxorubicin—ovarian cancer	3.96e-05	0.000242	CcSEcCtD
Clomipramine—Fatigue—Doxorubicin—ovarian cancer	3.95e-05	0.000242	CcSEcCtD
Clomipramine—Urticaria—Epirubicin—ovarian cancer	3.94e-05	0.000241	CcSEcCtD
Clomipramine—Pain—Doxorubicin—ovarian cancer	3.92e-05	0.00024	CcSEcCtD
Clomipramine—Constipation—Doxorubicin—ovarian cancer	3.92e-05	0.00024	CcSEcCtD
Clomipramine—Abdominal pain—Epirubicin—ovarian cancer	3.92e-05	0.000239	CcSEcCtD
Clomipramine—Body temperature increased—Epirubicin—ovarian cancer	3.92e-05	0.000239	CcSEcCtD
Clomipramine—Feeling abnormal—Doxorubicin—ovarian cancer	3.78e-05	0.000231	CcSEcCtD
Clomipramine—Gastrointestinal pain—Doxorubicin—ovarian cancer	3.75e-05	0.000229	CcSEcCtD
Clomipramine—Hypersensitivity—Epirubicin—ovarian cancer	3.65e-05	0.000223	CcSEcCtD
Clomipramine—Urticaria—Doxorubicin—ovarian cancer	3.64e-05	0.000223	CcSEcCtD
Clomipramine—Abdominal pain—Doxorubicin—ovarian cancer	3.62e-05	0.000222	CcSEcCtD
Clomipramine—Body temperature increased—Doxorubicin—ovarian cancer	3.62e-05	0.000222	CcSEcCtD
Clomipramine—Asthenia—Epirubicin—ovarian cancer	3.56e-05	0.000217	CcSEcCtD
Clomipramine—Chlorprothixene—ABCB1—ovarian cancer	3.55e-05	0.0847	CrCbGaD
Clomipramine—Pruritus—Epirubicin—ovarian cancer	3.51e-05	0.000214	CcSEcCtD
Clomipramine—Diarrhoea—Epirubicin—ovarian cancer	3.39e-05	0.000207	CcSEcCtD
Clomipramine—Hypersensitivity—Doxorubicin—ovarian cancer	3.38e-05	0.000206	CcSEcCtD
Clomipramine—Flurazepam—ABCB1—ovarian cancer	3.32e-05	0.0791	CrCbGaD
Clomipramine—Asthenia—Doxorubicin—ovarian cancer	3.29e-05	0.000201	CcSEcCtD
Clomipramine—Trimipramine—ABCB1—ovarian cancer	3.28e-05	0.0782	CrCbGaD
Clomipramine—Dizziness—Epirubicin—ovarian cancer	3.28e-05	0.0002	CcSEcCtD
Clomipramine—Pruritus—Doxorubicin—ovarian cancer	3.24e-05	0.000198	CcSEcCtD
Clomipramine—Promethazine—ABCB1—ovarian cancer	3.16e-05	0.0753	CrCbGaD
Clomipramine—Vomiting—Epirubicin—ovarian cancer	3.15e-05	0.000193	CcSEcCtD
Clomipramine—Diarrhoea—Doxorubicin—ovarian cancer	3.14e-05	0.000192	CcSEcCtD
Clomipramine—Doxepin—ABCB1—ovarian cancer	3.13e-05	0.0746	CrCbGaD
Clomipramine—Rash—Epirubicin—ovarian cancer	3.12e-05	0.000191	CcSEcCtD
Clomipramine—Dermatitis—Epirubicin—ovarian cancer	3.12e-05	0.000191	CcSEcCtD
Clomipramine—Trifluoperazine—ABCB1—ovarian cancer	3.12e-05	0.0743	CrCbGaD
Clomipramine—Headache—Epirubicin—ovarian cancer	3.1e-05	0.00019	CcSEcCtD
Clomipramine—Dizziness—Doxorubicin—ovarian cancer	3.03e-05	0.000185	CcSEcCtD
Clomipramine—Nausea—Epirubicin—ovarian cancer	2.94e-05	0.00018	CcSEcCtD
Clomipramine—Vomiting—Doxorubicin—ovarian cancer	2.92e-05	0.000178	CcSEcCtD
Clomipramine—Rash—Doxorubicin—ovarian cancer	2.89e-05	0.000177	CcSEcCtD
Clomipramine—Dermatitis—Doxorubicin—ovarian cancer	2.89e-05	0.000177	CcSEcCtD
Clomipramine—Desipramine—ABCB1—ovarian cancer	2.87e-05	0.0684	CrCbGaD
Clomipramine—Headache—Doxorubicin—ovarian cancer	2.87e-05	0.000176	CcSEcCtD
Clomipramine—Nausea—Doxorubicin—ovarian cancer	2.72e-05	0.000166	CcSEcCtD
Clomipramine—Diazepam—ABCB1—ovarian cancer	2.64e-05	0.0628	CrCbGaD
Clomipramine—Chlorpromazine—ABCB1—ovarian cancer	2.45e-05	0.0583	CrCbGaD
Clomipramine—Imipramine—ABCB1—ovarian cancer	2.44e-05	0.058	CrCbGaD
Clomipramine—Amitriptyline—ABCB1—ovarian cancer	2.42e-05	0.0577	CrCbGaD
Clomipramine—HRH2—Signaling Pathways—MAPK1—ovarian cancer	3.5e-06	0.000187	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—EGFR—ovarian cancer	3.5e-06	0.000187	CbGpPWpGaD
Clomipramine—HTR6—Signaling by GPCR—IL6—ovarian cancer	3.49e-06	0.000186	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—PIK3CB—ovarian cancer	3.49e-06	0.000186	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—MTOR—ovarian cancer	3.49e-06	0.000186	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—SLC5A5—ovarian cancer	3.48e-06	0.000186	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—PIK3CG—ovarian cancer	3.47e-06	0.000185	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—IL2—ovarian cancer	3.46e-06	0.000185	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—TERT—ovarian cancer	3.44e-06	0.000184	CbGpPWpGaD
Clomipramine—ALB—Hemostasis—KRAS—ovarian cancer	3.43e-06	0.000183	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—CCND1—ovarian cancer	3.42e-06	0.000183	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—ABCB1—ovarian cancer	3.41e-06	0.000182	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—CTNNB1—ovarian cancer	3.39e-06	0.000181	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—PPP2R1A—ovarian cancer	3.38e-06	0.00018	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—ESR1—ovarian cancer	3.37e-06	0.00018	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—SLC2A1—ovarian cancer	3.36e-06	0.00018	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—YAP1—ovarian cancer	3.35e-06	0.000179	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—CXCL8—ovarian cancer	3.35e-06	0.000179	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—TYMS—ovarian cancer	3.35e-06	0.000179	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—MAPK1—ovarian cancer	3.35e-06	0.000179	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—EGFR—ovarian cancer	3.35e-06	0.000179	CbGpPWpGaD
Clomipramine—HTR2B—Signaling by GPCR—HRAS—ovarian cancer	3.33e-06	0.000178	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—MMP9—ovarian cancer	3.32e-06	0.000177	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—IL6ST—ovarian cancer	3.32e-06	0.000177	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—KRAS—ovarian cancer	3.31e-06	0.000177	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—PTEN—ovarian cancer	3.3e-06	0.000176	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	3.29e-06	0.000176	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—CDKN1B—ovarian cancer	3.27e-06	0.000175	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—TYMS—ovarian cancer	3.27e-06	0.000175	CbGpPWpGaD
Clomipramine—ADRA2A—Hemostasis—AKT1—ovarian cancer	3.27e-06	0.000174	CbGpPWpGaD
Clomipramine—HTR2B—GPCR downstream signaling—AKT1—ovarian cancer	3.24e-06	0.000173	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—PIK3CD—ovarian cancer	3.23e-06	0.000172	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—CYP1B1—ovarian cancer	3.23e-06	0.000172	CbGpPWpGaD
Clomipramine—HTR6—Signaling by GPCR—AKT1—ovarian cancer	3.22e-06	0.000172	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—CASP3—ovarian cancer	3.21e-06	0.000171	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—IL2—ovarian cancer	3.2e-06	0.000171	CbGpPWpGaD
Clomipramine—HTR2C—GPCR downstream signaling—PIK3CA—ovarian cancer	3.2e-06	0.000171	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—PIK3CG—ovarian cancer	3.19e-06	0.00017	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—APC—ovarian cancer	3.19e-06	0.00017	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—NRAS—ovarian cancer	3.19e-06	0.00017	CbGpPWpGaD
Clomipramine—HTR2B—Signaling by GPCR—IL6—ovarian cancer	3.19e-06	0.00017	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—CAV1—ovarian cancer	3.18e-06	0.00017	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—KRAS—ovarian cancer	3.16e-06	0.000169	CbGpPWpGaD
Clomipramine—ALB—Hemostasis—PIK3CA—ovarian cancer	3.15e-06	0.000168	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—ABCB1—ovarian cancer	3.14e-06	0.000167	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—CCND1—ovarian cancer	3.12e-06	0.000167	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—CTNNB1—ovarian cancer	3.09e-06	0.000165	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—TYMS—ovarian cancer	3.08e-06	0.000164	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—ESR1—ovarian cancer	3.07e-06	0.000164	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—MAPK3—ovarian cancer	3.05e-06	0.000163	CbGpPWpGaD
Clomipramine—ALB—Hemostasis—TP53—ovarian cancer	3.05e-06	0.000163	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—PIK3CD—ovarian cancer	3.05e-06	0.000163	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—PIK3CA—ovarian cancer	3.04e-06	0.000162	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—MMP9—ovarian cancer	3.03e-06	0.000162	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—IL6ST—ovarian cancer	3.02e-06	0.000161	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—PTEN—ovarian cancer	3.01e-06	0.000161	CbGpPWpGaD
Clomipramine—ALB—Metabolism—CAV1—ovarian cancer	3.01e-06	0.000161	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—VEGFA—ovarian cancer	2.98e-06	0.000159	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—STAT3—ovarian cancer	2.95e-06	0.000158	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—NRAS—ovarian cancer	2.95e-06	0.000157	CbGpPWpGaD
Clomipramine—HTR2B—Signaling by GPCR—AKT1—ovarian cancer	2.94e-06	0.000157	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—TP53—ovarian cancer	2.94e-06	0.000157	CbGpPWpGaD
Clomipramine—ALB—Hemostasis—HRAS—ovarian cancer	2.92e-06	0.000156	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—MAPK1—ovarian cancer	2.91e-06	0.000155	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—EGFR—ovarian cancer	2.9e-06	0.000155	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—PIK3CA—ovarian cancer	2.9e-06	0.000155	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—APC—ovarian cancer	2.9e-06	0.000155	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—PIK3CG—ovarian cancer	2.9e-06	0.000155	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—NRAS—ovarian cancer	2.9e-06	0.000155	CbGpPWpGaD
Clomipramine—ALB—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.87e-06	0.000153	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—PPP2R1A—ovarian cancer	2.86e-06	0.000153	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—ERBB2—ovarian cancer	2.85e-06	0.000152	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	2.85e-06	0.000152	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—MAPK3—ovarian cancer	2.82e-06	0.000151	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—MTOR—ovarian cancer	2.81e-06	0.00015	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—PIK3CB—ovarian cancer	2.81e-06	0.00015	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—HRAS—ovarian cancer	2.81e-06	0.00015	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—PIK3CD—ovarian cancer	2.8e-06	0.00015	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—MAPK3—ovarian cancer	2.78e-06	0.000148	CbGpPWpGaD
Clomipramine—HTR2A—GPCR downstream signaling—PIK3CA—ovarian cancer	2.78e-06	0.000148	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—KRAS—ovarian cancer	2.74e-06	0.000147	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—MYC—ovarian cancer	2.74e-06	0.000147	CbGpPWpGaD
Clomipramine—ALB—Metabolism—PIK3CG—ovarian cancer	2.74e-06	0.000146	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—FASN—ovarian cancer	2.73e-06	0.000146	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—VEGFA—ovarian cancer	2.72e-06	0.000145	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—CXCL8—ovarian cancer	2.7e-06	0.000144	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—CAV1—ovarian cancer	2.7e-06	0.000144	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—STAT3—ovarian cancer	2.7e-06	0.000144	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—IL6—ovarian cancer	2.69e-06	0.000144	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—SLC5A5—ovarian cancer	2.69e-06	0.000144	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—NRAS—ovarian cancer	2.69e-06	0.000144	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—HRAS—ovarian cancer	2.69e-06	0.000143	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—MAPK1—ovarian cancer	2.68e-06	0.000143	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—EGFR—ovarian cancer	2.68e-06	0.000143	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—PIK3CB—ovarian cancer	2.66e-06	0.000142	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—ABCB1—ovarian cancer	2.66e-06	0.000142	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—MAPK1—ovarian cancer	2.64e-06	0.000141	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—EGFR—ovarian cancer	2.64e-06	0.000141	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—CDKN1B—ovarian cancer	2.64e-06	0.000141	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—CAV1—ovarian cancer	2.63e-06	0.000141	CbGpPWpGaD
Clomipramine—HTR2C—GPCR downstream signaling—AKT1—ovarian cancer	2.61e-06	0.000139	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—TYMS—ovarian cancer	2.61e-06	0.000139	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—SLC2A1—ovarian cancer	2.6e-06	0.000139	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—CASP3—ovarian cancer	2.59e-06	0.000138	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—IL2—ovarian cancer	2.58e-06	0.000138	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.58e-06	0.000138	CbGpPWpGaD
Clomipramine—ALB—Hemostasis—AKT1—ovarian cancer	2.58e-06	0.000138	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—MAPK3—ovarian cancer	2.57e-06	0.000138	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—IL6—ovarian cancer	2.57e-06	0.000137	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—PIK3CD—ovarian cancer	2.55e-06	0.000136	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—KRAS—ovarian cancer	2.54e-06	0.000135	CbGpPWpGaD
Clomipramine—ADRA2A—GPCR downstream signaling—PIK3CA—ovarian cancer	2.53e-06	0.000135	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—PIK3CA—ovarian cancer	2.52e-06	0.000135	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—CCND1—ovarian cancer	2.52e-06	0.000135	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—MYC—ovarian cancer	2.5e-06	0.000134	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—KRAS—ovarian cancer	2.5e-06	0.000133	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—CTNNB1—ovarian cancer	2.49e-06	0.000133	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—CYP1B1—ovarian cancer	2.49e-06	0.000133	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—CAV1—ovarian cancer	2.48e-06	0.000133	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—AKT1—ovarian cancer	2.48e-06	0.000132	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—ERBB2—ovarian cancer	2.48e-06	0.000132	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—PIK3CG—ovarian cancer	2.46e-06	0.000131	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—MAPK1—ovarian cancer	2.45e-06	0.000131	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—EGFR—ovarian cancer	2.45e-06	0.000131	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—MMP9—ovarian cancer	2.45e-06	0.000131	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—PIK3CB—ovarian cancer	2.44e-06	0.00013	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—MTOR—ovarian cancer	2.44e-06	0.00013	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—PTEN—ovarian cancer	2.43e-06	0.00013	CbGpPWpGaD
Clomipramine—ALB—Metabolism—PIK3CD—ovarian cancer	2.41e-06	0.000129	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—PIK3CG—ovarian cancer	2.4e-06	0.000128	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—AKT1—ovarian cancer	2.37e-06	0.000127	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—CXCL8—ovarian cancer	2.35e-06	0.000125	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—HRAS—ovarian cancer	2.33e-06	0.000125	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—PIK3CA—ovarian cancer	2.33e-06	0.000124	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—KRAS—ovarian cancer	2.31e-06	0.000124	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—PTEN—ovarian cancer	2.3e-06	0.000123	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—PIK3CA—ovarian cancer	2.29e-06	0.000123	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—CDKN1B—ovarian cancer	2.29e-06	0.000122	CbGpPWpGaD
Clomipramine—HTR2A—GPCR downstream signaling—AKT1—ovarian cancer	2.27e-06	0.000121	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—PIK3CG—ovarian cancer	2.26e-06	0.000121	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—TP53—ovarian cancer	2.25e-06	0.00012	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—ERBB2—ovarian cancer	2.25e-06	0.00012	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—CASP3—ovarian cancer	2.25e-06	0.00012	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—IL2—ovarian cancer	2.24e-06	0.00012	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—IL6—ovarian cancer	2.23e-06	0.000119	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—PIK3CB—ovarian cancer	2.22e-06	0.000119	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—MTOR—ovarian cancer	2.22e-06	0.000119	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	2.21e-06	0.000118	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—VEGFA—ovarian cancer	2.2e-06	0.000117	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—CCND1—ovarian cancer	2.19e-06	0.000117	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—STAT3—ovarian cancer	2.17e-06	0.000116	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—NRAS—ovarian cancer	2.17e-06	0.000116	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—CTNNB1—ovarian cancer	2.17e-06	0.000116	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—PIK3CD—ovarian cancer	2.16e-06	0.000115	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—HRAS—ovarian cancer	2.15e-06	0.000115	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—CXCL8—ovarian cancer	2.14e-06	0.000114	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—PIK3CA—ovarian cancer	2.13e-06	0.000114	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—MMP9—ovarian cancer	2.12e-06	0.000113	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—HRAS—ovarian cancer	2.12e-06	0.000113	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—PTEN—ovarian cancer	2.11e-06	0.000113	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—PIK3CD—ovarian cancer	2.11e-06	0.000113	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—CAV1—ovarian cancer	2.1e-06	0.000112	CbGpPWpGaD
Clomipramine—ALB—Metabolism—PIK3CB—ovarian cancer	2.1e-06	0.000112	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—CDKN1B—ovarian cancer	2.09e-06	0.000111	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—MAPK3—ovarian cancer	2.08e-06	0.000111	CbGpPWpGaD
Clomipramine—ADRA2A—GPCR downstream signaling—AKT1—ovarian cancer	2.06e-06	0.00011	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—IL6—ovarian cancer	2.06e-06	0.00011	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—AKT1—ovarian cancer	2.06e-06	0.00011	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—TP53—ovarian cancer	2.06e-06	0.00011	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—ABCB1—ovarian cancer	2.05e-06	0.00011	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—CASP3—ovarian cancer	2.04e-06	0.000109	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—IL2—ovarian cancer	2.04e-06	0.000109	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—IL6—ovarian cancer	2.03e-06	0.000108	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—MYC—ovarian cancer	2.02e-06	0.000108	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—TYMS—ovarian cancer	2.01e-06	0.000108	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.01e-06	0.000107	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—CCND1—ovarian cancer	1.99e-06	0.000106	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—PIK3CD—ovarian cancer	1.99e-06	0.000106	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—MAPK1—ovarian cancer	1.98e-06	0.000106	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—EGFR—ovarian cancer	1.98e-06	0.000106	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—CTNNB1—ovarian cancer	1.97e-06	0.000105	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—HRAS—ovarian cancer	1.97e-06	0.000105	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—MMP9—ovarian cancer	1.93e-06	0.000103	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—PTEN—ovarian cancer	1.92e-06	0.000103	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—PIK3CG—ovarian cancer	1.92e-06	0.000102	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—VEGFA—ovarian cancer	1.91e-06	0.000102	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—AKT1—ovarian cancer	1.9e-06	0.000102	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—STAT3—ovarian cancer	1.89e-06	0.000101	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—NRAS—ovarian cancer	1.88e-06	0.000101	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—PIK3CB—ovarian cancer	1.88e-06	0.000101	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—IL6—ovarian cancer	1.88e-06	0.000101	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—AKT1—ovarian cancer	1.87e-06	0.0001	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—KRAS—ovarian cancer	1.87e-06	9.97e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—PIK3CB—ovarian cancer	1.84e-06	9.82e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—PTEN—ovarian cancer	1.81e-06	9.68e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—MAPK3—ovarian cancer	1.8e-06	9.63e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—MYC—ovarian cancer	1.75e-06	9.37e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—AKT1—ovarian cancer	1.74e-06	9.28e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—VEGFA—ovarian cancer	1.73e-06	9.27e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—PIK3CB—ovarian cancer	1.73e-06	9.25e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—STAT3—ovarian cancer	1.72e-06	9.17e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—MAPK1—ovarian cancer	1.72e-06	9.17e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—EGFR—ovarian cancer	1.72e-06	9.17e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—PIK3CA—ovarian cancer	1.72e-06	9.16e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—NRAS—ovarian cancer	1.71e-06	9.15e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—PIK3CD—ovarian cancer	1.68e-06	8.99e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—TP53—ovarian cancer	1.66e-06	8.86e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—MAPK3—ovarian cancer	1.64e-06	8.77e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—PTEN—ovarian cancer	1.63e-06	8.69e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—CAV1—ovarian cancer	1.62e-06	8.67e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—KRAS—ovarian cancer	1.62e-06	8.66e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—PIK3CA—ovarian cancer	1.62e-06	8.65e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—MYC—ovarian cancer	1.6e-06	8.52e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—PTEN—ovarian cancer	1.59e-06	8.48e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—HRAS—ovarian cancer	1.59e-06	8.47e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—MAPK1—ovarian cancer	1.56e-06	8.34e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—EGFR—ovarian cancer	1.56e-06	8.34e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—IL6—ovarian cancer	1.52e-06	8.11e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—PTEN—ovarian cancer	1.5e-06	7.99e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—PIK3CA—ovarian cancer	1.49e-06	7.95e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—PIK3CG—ovarian cancer	1.48e-06	7.89e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—KRAS—ovarian cancer	1.47e-06	7.88e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—PIK3CB—ovarian cancer	1.47e-06	7.84e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—TP53—ovarian cancer	1.44e-06	7.7e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—AKT1—ovarian cancer	1.4e-06	7.48e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—HRAS—ovarian cancer	1.38e-06	7.36e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—PIK3CA—ovarian cancer	1.35e-06	7.24e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—AKT1—ovarian cancer	1.32e-06	7.07e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—IL6—ovarian cancer	1.32e-06	7.04e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—TP53—ovarian cancer	1.31e-06	7e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—PIK3CD—ovarian cancer	1.3e-06	6.94e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—PIK3CA—ovarian cancer	1.28e-06	6.83e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—PTEN—ovarian cancer	1.27e-06	6.77e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—HRAS—ovarian cancer	1.25e-06	6.7e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—AKT1—ovarian cancer	1.22e-06	6.5e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—IL6—ovarian cancer	1.2e-06	6.41e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—PIK3CA—ovarian cancer	1.15e-06	6.13e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—PIK3CB—ovarian cancer	1.13e-06	6.05e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—PIK3CA—ovarian cancer	1.12e-06	5.98e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—AKT1—ovarian cancer	1.11e-06	5.91e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—PIK3CA—ovarian cancer	1.06e-06	5.64e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—AKT1—ovarian cancer	1.04e-06	5.58e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—PTEN—ovarian cancer	9.79e-07	5.23e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—AKT1—ovarian cancer	9.38e-07	5.01e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—AKT1—ovarian cancer	9.15e-07	4.89e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—PIK3CA—ovarian cancer	8.95e-07	4.78e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—AKT1—ovarian cancer	8.63e-07	4.61e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—AKT1—ovarian cancer	7.31e-07	3.9e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—PIK3CA—ovarian cancer	6.9e-07	3.69e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—AKT1—ovarian cancer	5.64e-07	3.01e-05	CbGpPWpGaD
